ERBB2 and gastric cancer: In this study, considering patients in ICI and HER2‐targeted cohorts that shared identical HER2/ERBB2 and TMB status and similar clinical features (comparable age and gender distribution, both in advanced stage), we speculated that immunotherapy might be a better option than HER2‐targeted therapy for advanced GC patients with positive HER2 and high TMB.